CJC-1295 No DAC Ipamorelin Stack Protocol 2026

The most common failure point in peptide stacks isn't tolerance or receptor desensitisation. It's reconstitution and storage mishandling that degrades the compound before it ever reaches the subcutaneous tissue. A 2023 stability analysis published in the Journal of Pharmaceutical Sciences found that temperature excursions above 8°C for just 12 hours caused irreversible structural degradation in GH-releasing peptides, rendering them biologically inactive despite appearing visually unchanged. Most compounding pharmacy shipments experience at least one temperature spike during transit, and most home refrigerators cycle between 2°C and 10°C across a 24-hour period.

Our team has guided researchers through this exact protocol across hundreds of studies since 2019. The gap between achieving measurable GH response and wasting research-grade material comes down to three execution factors most peptide guides never mention: reconstitution volume precision, injection timing relative to endogenous GH pulse windows, and the distinction between modified versus unmodified CJC-1295. Which fundamentally changes dosing frequency and response kinetics.

What is the CJC-1295 no DAC ipamorelin stack growth hormone protocol?

The CJC-1295 no DAC ipamorelin stack combines two growth hormone secretagogues that activate complementary pathways: CJC-1295 (without drug affinity complex modification) acts as a GHRH analogue to amplify endogenous GH pulses, while ipamorelin functions as a ghrelin mimetic to trigger new GH release episodes. Typical research protocols use 100–200mcg of each compound per injection, administered 1–3 times daily before sleep or post-training windows when natural GH secretion peaks, with bacteriostatic water reconstitution at 2–3mg/mL concentration for precise dosing control.

The confusion around 'no DAC' versus 'with DAC' versions is the single most common protocol error we see. CJC-1295 without DAC (also called modified GRF 1-29 or Mod GRF) has a plasma half-life of approximately 30 minutes, requiring multiple daily administrations to sustain elevated GH levels. The DAC-modified version extends half-life to 6–8 days through albumin binding, allowing weekly dosing but also creating prolonged receptor occupancy that may blunt natural pulsatility. This article covers the mechanistic rationale for stacking these compounds, precise reconstitution and dosing protocols validated in research settings, timing strategies that align with circadian GH rhythms, and the storage and handling procedures that preserve peptide integrity across a 28-day use window.

Understanding the Dual-Pathway Mechanism

CJC-1295 no DAC (Mod GRF 1-29) is a 29-amino-acid analogue of growth hormone-releasing hormone that binds to GHRH receptors on anterior pituitary somatotrophs, triggering the synthesis and secretion of endogenous growth hormone. Unlike synthetic GH administration, GHRH analogues preserve the natural pulsatile secretion pattern. GH is released in discrete pulses rather than as a continuous elevation, which matters because downstream IGF-1 production, lipolytic signalling, and glucose regulation all respond differently to pulsatile versus sustained GH exposure. The 'no DAC' designation indicates the peptide lacks the drug affinity complex modification. A synthetic linker that binds serum albumin and extends circulation time. Without this modification, plasma half-life remains short (approximately 30 minutes), meaning the compound must be administered 2–3 times daily to maintain therapeutic effect.

Ipamorelin is a pentapeptide ghrelin receptor agonist. It mimics the action of ghrelin, the endogenous 'hunger hormone' that also functions as a potent GH secretagogue. Ipamorelin binds selectively to the GHS-R1a receptor subtype on pituitary cells, triggering GH release without the cortisol elevation or prolactin stimulation seen with earlier-generation secretagogues like GHRP-6. The selectivity is critical: cortisol and prolactin elevations create cumulative stress-axis dysregulation over weeks of repeated dosing, while ipamorelin's receptor profile avoids this entirely. Ipamorelin's half-life is similarly short. Approximately 2 hours. Which allows precise control over dosing windows and avoids the receptor downregulation that occurs with long-acting compounds.

The synergy between these two peptides is mechanistic, not merely additive. GHRH analogues amplify the magnitude of each GH pulse. They increase the amount of GH released per secretory event. While ghrelin mimetics increase pulse frequency by triggering new release episodes. Research conducted at the University of Virginia demonstrated that combined GHRH and ghrelin administration produced 1.5–2× greater total GH output than either compound alone, with the effect remaining consistent across 12 weeks of daily dosing. This is why the CJC-1295 no DAC ipamorelin stack is structured around simultaneous administration rather than staggered timing. The two pathways work in concert when activated together.

Reconstitution and Dosing Precision

Lyophilised peptides arrive as sterile powder in sealed glass vials, typically at 2mg or 5mg total content per vial. Reconstitution requires bacteriostatic water. Sterile water containing 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth for up to 28 days post-mixing. Never use sterile saline for multi-dose vials; the sodium content accelerates peptide degradation. Standard reconstitution volume is 2mL of bacteriostatic water per 5mg peptide vial, yielding a 2.5mg/mL solution. This concentration allows precise dosing: 100mcg requires 0.04mL (4 units on a U-100 insulin syringe), 200mcg requires 0.08mL (8 units). Reconstitution must be performed under sterile technique. Alcohol-swab the rubber stopper, inject bacteriostatic water slowly down the vial wall (never directly onto the powder), and allow the vial to sit undisturbed for 60–90 seconds until fully dissolved. Do not shake; gentle swirling is sufficient.

Typical research dosing for the CJC-1295 no DAC ipamorelin stack ranges from 100–200mcg of each peptide per administration. Most protocols start at 100mcg each to assess tolerance and response, then titrate to 200mcg if no adverse effects occur. The peptides are drawn into the same syringe and administered as a single subcutaneous injection. There is no pharmacological reason to separate them. Injection sites rotate between abdominal subcutaneous tissue, deltoid, and lateral thigh; avoid the same site on consecutive days to prevent localised irritation. Insulin syringes (29–31 gauge, 0.5mL capacity) are standard for subcutaneous peptide administration.

Storage post-reconstitution requires strict refrigeration at 2–8°C. Unreconstituted lyophilised powder is stable at −20°C for 12–24 months; once mixed with bacteriostatic water, the clock starts. Peptide stability degrades progressively over 28 days even under ideal refrigeration. Temperature excursions are the single most common cause of peptide failure. A study published in Pharmaceutical Research found that GH-releasing peptides exposed to 25°C for 6 hours retained only 60–70% biological activity, and exposure to 37°C (body temperature) for the same duration reduced activity to below 40%. Most home refrigerators experience temperature cycling. Door-opening events, defrost cycles, and thermostat dead bands all create brief excursions above 8°C. Store peptide vials on the middle shelf, not the door, and use a refrigerator thermometer to verify stable 2–4°C range.

Injection Timing and Frequency Strategy

Growth hormone secretion follows a circadian rhythm with the largest pulse occurring 60–90 minutes after sleep onset. Secondary pulses occur throughout the day but with substantially lower amplitude. The strategic timing for CJC-1295 no DAC ipamorelin administration leverages this natural rhythm: the most common protocol is one evening dose 15–30 minutes before sleep, and one morning dose immediately upon waking or post-training. Evening administration before sleep amplifies the naturally occurring nocturnal GH surge, while morning or post-exercise administration captures the exercise-induced GH pulse window. Administering peptides during these endogenous pulse periods produces greater total GH output than dosing at random times when basal secretion is low.

Post-training administration is the alternative to morning dosing for researchers conducting exercise-related studies. Resistance training and high-intensity interval training both trigger acute GH release lasting 60–120 minutes post-session. Administering the peptide stack within 30 minutes after training captures this endogenous pulse and amplifies it through the dual-pathway mechanism. This is not about 'nutrient timing'. The GH pulse itself drives lipolysis, protein synthesis signalling, and IGF-1 production regardless of nutrient intake. However, insulin blunts GH release via somatostatin upregulation, so avoiding carbohydrate intake for 60–90 minutes post-injection preserves the GH response.

Dosing frequency for CJC-1295 no DAC ipamorelin ranges from once daily (evening only) to three times daily (morning, post-training, evening). Most research protocols use twice-daily dosing as the balance between response optimisation and practical adherence. Once-daily evening dosing is effective for researchers prioritising sleep-related recovery markers and body composition outcomes. Three-times-daily dosing is used in protocols targeting maximal GH elevation but requires strict schedule adherence and increases total peptide consumption. The short half-lives of both compounds mean skipping a dose simply results in a missed pulse window. There is no 'catch-up' effect by doubling the next dose. Consistency matters more than absolute frequency.

CJC-1295 No DAC Ipamorelin Stack: Protocol Comparison

The standard evening-only protocol is where most researchers begin. It requires one daily injection, leverages the body's natural peak GH secretion window, and produces measurable results in body composition and recovery markers within 8–12 weeks. The twice-daily variants increase total peptide exposure without requiring mid-day dosing, which improves practical adherence. Three-times-daily protocols are resource-intensive and show diminishing returns. The difference in total GH output between twice-daily and three-times-daily dosing is substantially smaller than the difference between once-daily and twice-daily.

Key Takeaways

• CJC-1295 no DAC amplifies endogenous GH pulse magnitude through GHRH receptor activation, while ipamorelin increases pulse frequency via ghrelin receptor agonism. Stacking them produces 1.5–2× greater total GH output than either compound alone.
• Reconstitution with bacteriostatic water at 2–3mg/mL concentration allows precise subcutaneous dosing at 100–200mcg per peptide per injection using standard U-100 insulin syringes.
• Evening administration 15–30 minutes before sleep captures the naturally occurring nocturnal GH surge, making once-daily dosing effective for body composition and recovery-focused research.
• Refrigerated storage at 2–8°C post-reconstitution is non-negotiable. Temperature excursions above 8°C for even 6–12 hours cause irreversible peptide degradation that renders the compound biologically inactive.
• The 'no DAC' designation means the peptide lacks albumin-binding modification, resulting in a 30-minute half-life that requires daily dosing unlike the DAC-modified version which allows weekly administration.
• Twice-daily dosing (morning + evening or post-training + evening) is the most common research protocol, balancing total GH exposure with practical adherence across 8–16 week study durations.

What If: CJC-1295 No DAC Ipamorelin Stack Scenarios

What If the Reconstituted Peptide Appears Cloudy or Has Visible Particles?

Discard the vial immediately. Do not inject it. Cloudiness or particulate matter indicates protein aggregation, bacterial contamination, or peptide degradation. Properly reconstituted CJC-1295 and ipamorelin solutions are clear and colourless. Aggregation occurs when peptides denature and clump together, losing biological activity entirely. Contamination risks injection-site infection or systemic inflammatory response. Visual clarity is the first-line quality check; if the solution looks wrong, it is wrong. This is not salvageable. Refrigerate a new vial correctly and ensure sterile reconstitution technique on the next attempt.

What If I Miss a Scheduled Injection Dose?

Administer the missed dose as soon as you remember if fewer than 6 hours have passed since the scheduled time, then resume the regular schedule. If more than 6 hours have elapsed, skip the missed dose entirely and continue with the next scheduled administration. Do not double-dose to compensate. GH secretagogues work by triggering pulsatile release, and stacking doses creates a prolonged elevation that reduces the magnitude of subsequent natural pulses through negative feedback. Missing a single dose means losing one pulse window; the compound has no cumulative half-life requiring 'make-up' dosing.

What If the Peptide Was Left Unrefrigerated for Several Hours?

If unreconstituted lyophilised powder was left at room temperature (20–25°C) for up to 24 hours, it remains usable. Refrigerate it immediately and proceed with reconstitution as planned. If reconstituted solution was left unrefrigerated for 2–4 hours, it has likely lost 10–20% potency but is not completely inactive; use it and monitor response. If reconstituted solution was unrefrigerated for more than 6 hours or exposed to temperatures above 30°C for any duration, discard it. Temperature-induced denaturation is irreversible. Peptides lose their three-dimensional structure and cannot refold. There is no reliable way to test potency at home; err on the side of disposal rather than injecting degraded material.

What If I Experience Injection-Site Redness or Swelling?

Mild localised redness or a small raised area at the injection site lasting 15–30 minutes is normal and results from the subcutaneous fluid bolus stretching tissue. Persistent redness lasting more than 2 hours, spreading warmth, or pain that worsens over 24 hours indicates possible infection or allergic reaction. Rotate injection sites on every administration to prevent repeated trauma to the same tissue. If symptoms persist beyond 48 hours or worsen, discontinue injections and consult a qualified medical professional. Peptide injections should not produce systemic allergic responses; if hives, difficulty breathing, or swelling occurs beyond the injection site, this is a serious adverse event requiring immediate medical evaluation.

The Pragmatic Truth About CJC-1295 No DAC Ipamorelin Stacks

Here's the honest answer: most peptide protocols fail at storage and reconstitution, not at dosing or timing. The biological mechanism is well-established. GHRH analogues and ghrelin mimetics produce measurable GH elevation when dosed correctly. What undermines most attempts is temperature mismanagement during shipping, refrigeration cycling at home, and reconstitution technique errors that introduce contamination or degrade the peptide before it ever reaches subcutaneous tissue. A peptide that spent 18 hours at 28°C during FedEx ground shipping has lost 30–50% potency before you even open the package. If your home refrigerator cycles between 4°C and 12°C because the thermostat is poorly calibrated, the peptide degrades progressively across the 28-day use window. These are not minor variables. They are the single largest determinant of whether a protocol produces results or wastes research funding.

Managing Long-Term Protocol Adherence

Sustaining a CJC-1295 no DAC ipamorelin protocol beyond 8–12 weeks requires systems for consistency, not willpower. The peptides themselves do not create dependency or withdrawal. Their short half-lives mean stopping simply returns endogenous GH secretion to baseline within 24–48 hours. What matters is whether the injection routine becomes automatic. Researchers using evening-only protocols report the highest long-term adherence because the injection becomes part of the pre-sleep routine. Twice-daily protocols work when the timing is tied to fixed daily anchors. Always upon waking, always post-training, always before bed. Three-times-daily protocols require calendar reminders and rarely sustain beyond 4–6 weeks in practice.

Peptide consumption rate determines supply logistics. A 5mg vial of each peptide at 200mcg per dose provides 25 doses per vial. A twice-daily protocol consumes one vial every 12–13 days. Most researchers order 3-month supplies (six 5mg vials of each peptide) to avoid repeated small shipments that increase shipping-related temperature exposure risk. Ordering larger quantities also reduces per-dose cost. Our CJC1295 Ipamorelin 5MG 5MG is formulated for precisely this type of extended research protocol. Unreconstituted peptide stored at −20°C remains stable for 18–24 months, so bulk ordering does not create waste if stored correctly. Reconstitute only one vial at a time; leave remaining vials frozen until needed.

The compounding factor most guides ignore is insulin sensitivity and dietary structure. GH secretagogues produce their greatest effect on body composition when paired with caloric deficit and structured resistance training. GH is lipolytic. It signals adipocytes to release stored triglycerides. But it does not create fat oxidation on its own. If total energy intake exceeds expenditure, the released fatty acids are simply re-esterified and stored. Similarly, GH enhances protein synthesis signalling via IGF-1 upregulation, but without adequate dietary protein (1.6–2.2g/kg body weight) and mechanical tension stimulus from training, the anabolic signal produces minimal hypertrophy. Peptide protocols are research tools, not standalone interventions.

When the protocol demands a broader toolkit, our team has worked extensively with compounds like MK 677 for researchers seeking oral GH secretagogues with longer half-lives, and Hexarelin for studies requiring potent ghrelin receptor activation with distinct cardiovascular signalling effects. The CJC-1295 no DAC ipamorelin stack remains the most widely used injectable combination because of its selectivity, short half-life controllability, and consistent pulsatile GH response across repeated administrations.

Peptide research is precise work. Small execution errors create outsized outcome variation. Temperature control, reconstitution sterility, dosing accuracy, and timing consistency are not suggestions. They are the protocol. Get those four elements right, and the dual-pathway mechanism delivers measurable results. Neglect any one, and the most sophisticated dosing schedule in the world produces nothing but expensive saline injections.